Biomerica Statistics
Total Valuation
Biomerica has a market cap or net worth of $7.76 million. The enterprise value is $5.50 million.
Important Dates
The last earnings date was Wednesday, January 14, 2026, after market close.
| Earnings Date | Jan 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomerica has 3.02 million shares outstanding. The number of shares has increased by 24.19% in one year.
| Current Share Class | 3.02M |
| Shares Outstanding | 3.02M |
| Shares Change (YoY) | +24.19% |
| Shares Change (QoQ) | +10.21% |
| Owned by Insiders (%) | 9.73% |
| Owned by Institutions (%) | 2.94% |
| Float | 2.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.51 |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.25 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.30% and return on invested capital (ROIC) is -62.90%.
| Return on Equity (ROE) | -84.30% |
| Return on Assets (ROA) | -49.43% |
| Return on Invested Capital (ROIC) | -62.90% |
| Return on Capital Employed (ROCE) | -118.67% |
| Weighted Average Cost of Capital (WACC) | 4.67% |
| Revenue Per Employee | $82,537 |
| Profits Per Employee | -$74,537 |
| Employee Count | 54 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.54 |
Taxes
In the past 12 months, Biomerica has paid $10,000 in taxes.
| Income Tax | 10,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.46% in the last 52 weeks. The beta is 0.11, so Biomerica's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -46.46% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 3.05 |
| Relative Strength Index (RSI) | 49.12 |
| Average Volume (20 Days) | 149,299 |
Short Selling Information
The latest short interest is 92,289, so 3.06% of the outstanding shares have been sold short.
| Short Interest | 92,289 |
| Short Previous Month | 41,348 |
| Short % of Shares Out | 3.06% |
| Short % of Float | 3.39% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, Biomerica had revenue of $4.46 million and -$4.03 million in losses. Loss per share was -$1.54.
| Revenue | 4.46M |
| Gross Profit | 251,000 |
| Operating Income | -5.26M |
| Pretax Income | -4.01M |
| Net Income | -4.03M |
| EBITDA | -5.18M |
| EBIT | -5.26M |
| Loss Per Share | -$1.54 |
Full Income StatementBalance Sheet
The company has $2.54 million in cash and $284,000 in debt, with a net cash position of $2.26 million or $0.75 per share.
| Cash & Cash Equivalents | 2.54M |
| Total Debt | 284,000 |
| Net Cash | 2.26M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 4.44M |
| Book Value Per Share | 1.50 |
| Working Capital | 3.59M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.97M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.97M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
Gross margin is 5.63%, with operating and profit margins of -118.08% and -90.31%.
| Gross Margin | 5.63% |
| Operating Margin | -118.08% |
| Pretax Margin | -90.08% |
| Profit Margin | -90.31% |
| EBITDA Margin | -116.20% |
| EBIT Margin | -118.08% |
| FCF Margin | n/a |
Dividends & Yields
Biomerica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.19% |
| Shareholder Yield | -24.19% |
| Earnings Yield | -51.86% |
| FCF Yield | -38.20% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 21, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | Apr 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Biomerica has an Altman Z-Score of -10.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.75 |
| Piotroski F-Score | 3 |
